Journals International Journal of Neuro...

International Journal of Neuropsychopharmacology
Chengfeng Chen, Yongyan Deng, Yuling Li, Meiting Zhang, Tong Yu, Kun Xie, Wuyou Bao, Peiying Li, Ling Sun, Tianhong Zhang, Yikang Zhu, Bin Zhang
BACKGROUND: The efficacy of pharmacological and nutritional interventions in individuals at clinical high risk for psychosis (CHR-P) remains elusive. This study aims to investigate the efficacy of pharmacological and nutritional interventions in CHR-P and whether these interventions can enhance the efficacy of psychological treatments. METHODS: We systematically reviewed data from five databases until July 24, 2021: PubMed, Web of Science, EMBASE, China National Knowledge Infrastructure, and WanFang Data...
February 26, 2024: International Journal of Neuropsychopharmacology
Timothy G Dinan, John F Cryan
No abstract text is available yet for this article.
February 19, 2024: International Journal of Neuropsychopharmacology
Atheeshaan Arumuham, Matthew M Nour, Mattia Veronese, Katherine Beck, Ellis Chika Onwordi, David J Lythgoe, Sameer Jauhar, Eugenii A Rabiner, Oliver D Howes
BACKGROUND: The histamine-3 receptor (H3R) may have a role in cognitive processes, through its action as a presynaptic heteroreceptor inhibiting the release of glutamate in the brain. To explore this, we examined anterior cingulate cortex (ACC) and striatum H3R availability in patients with schizophrenia, and characterised their relationships with glutamate levels in corresponding brain regions. METHODS: We employed a cross-sectional study, recruiting 12 patients with schizophrenia and 12 healthy volunteers...
February 19, 2024: International Journal of Neuropsychopharmacology
Yan Chen, Wei Guan, Mei-Lan Wang, Xiao-Yun Lin
Economic development and increased stress have considerably increased the prevalence of psychiatric disorders in recent years, which rank as one of the most prevalent diseases globally. Several factors, including chronic social stress, genetic inheritance, and autogenous diseases, lead to the development and progression of psychiatric disorders. Clinical treatments for psychiatric disorders include psychotherapy, chemotherapy, and electric shock therapy. Although various achievements have been made researching psychiatric disorders, the pathogenesis of these diseases has not been fully understood yet, and serious side effects and resistance to antipsychotics are major obstacles to treating patients with psychiatric disorders...
February 14, 2024: International Journal of Neuropsychopharmacology
Xinyi Li, Zhenhao Shi, Dustin Todaro, Timothy Pond, Juliana Byanyima, Sianneh Vesslee, Rishika Reddy, Ravi Prakash Reddy Nanga, Gabriel Kass, Vijay Ramchandani, Henry R Kranzler, Janaina C M Vendruscolo, Leandro F Vendruscolo, Corinde E Wiers
BACKGROUND: Previous preclinical and human studies have shown that a high-fat ketogenic diet and ketone supplements (KS) are efficacious in reducing alcohol craving, alcohol consumption, and signs of alcohol withdrawal. However, the effects of KS on alcohol sensitivity are unknown. METHODS: In this single-blind, cross-over study, 10 healthy participants (3 females) were administered a single, oral dose of a KS (25 g of ketones from D-β-hydroxybutyric acid and R-1,3-butanediol) or placebo 30 min prior to an oral alcohol dose (0...
February 5, 2024: International Journal of Neuropsychopharmacology
Ibrahim Turkoz, Mehmet Daskiran, Uzma Siddiqui, R Karl Knight, Karen L Johnston, Christoph U Correll
BACKGROUND: The three paliperidone palmitate (PP) long-acting injectable antipsychotic formulations, PP 1-month (PP1M), PP 3-month (PP3M), and PP 6-month (PP6M) have shown to reduce the risk of relapse in schizophrenia. The current phase-4 study constructed external comparator arms (ECAs) using real-world data for PP3M and PP1M and compared relapse prevention rates to PP6M from an open-label extension (OLE) study in adult patients with schizophrenia. METHODS: PP6M data were derived from a single-arm, 24-month, OLE study (NCT04072575), which included patients with schizophrenia who completed a 12-month randomized, double-blind (DB), noninferiority, phase-3 study (NCT03345342), without relapse...
February 1, 2024: International Journal of Neuropsychopharmacology
Blake A Fordyce, Bryan L Roth
For centuries, ancient lineages have consumed psychedelic compounds from natural sources. In the modern era, scientists have since harnessed the power of computational tools, cellular assays, and behavioral metrics to study how these compounds instigate changes on molecular, cellular, circuit-wide, and system levels. Here, we provide a brief history of psychedelics and their use in science, medicine, and culture. We then outline current techniques for studying psychedelics from a pharmacological perspective...
January 30, 2024: International Journal of Neuropsychopharmacology
Alexandra Münster, Julia Huster, Susanne Sommer, Corinna Traxler, Angeline Votteler, Wolfgang Hauber
BACKGROUND: Acute stress alters risk-based decision making, however, the underlying neural and neurochemical substrates are underexplored. Given their well-documented stress-inducing effects in humans and laboratory animals, glucocorticoids such as cortisol and corticosterone and the α2-adrenoceptor antagonist yohimbine represent potent pharmacological tools to mimic some characteristics of acute stress. METHODS: Here, we analyzed the effects of the pharmacological stressors corticosterone and yohimbine given systemically on risk-based decision making in male rats...
January 12, 2024: International Journal of Neuropsychopharmacology
Raghunath Singh, Margaret K Hahn, Yashika Bansal, Sri Mahavir Agarwal, Gary Remington
No abstract text is available yet for this article.
January 9, 2024: International Journal of Neuropsychopharmacology
Astrid Prochnow, Moritz Mückschel, Elena Eggert, Jessica Senftleben, Christian Frings, Alexander Münchau, Veit Roessner, Annet Bluschke, Christian Beste
BACKGROUND: The catecholaminergic system influences response inhibition, but the magnitude of the impact of catecholaminergic manipulation is heterogeneous. Theoretical considerations suggest that the voluntary modulability of theta band activity can explain this variance. The study aimed to investigate to what extent interindividual differences in catecholaminergic effects on response inhibition depend on voluntary theta band activity modulation. METHODS: N=67 healthy adults were tested in a randomized, double-blind, cross-over study design...
January 5, 2024: International Journal of Neuropsychopharmacology
Alejandra Delgado-Sequera, Clara Garcia-Mompo, Ana Maria Gonzalez-Pinto, Hidalgo-Figueroa Maria, Berrocoso Esther
BACKGROUND: Cannabis use is a risk factor of psychiatric illness, such as bipolar disorder type-I (BDI). Indeed, cannabis use strongly influences the onset and clinical course of BDI, although the biological mechanisms underlying this interaction remain unknown. Therefore, we have reviewed the biological mechanisms affected by cannabis use that may trigger BD. METHODS: A systematic review was carried out of articles in which gene expression was studied in cannabis users or human-derived cells exposed to THC or CBD...
January 4, 2024: International Journal of Neuropsychopharmacology
Marcello Serra, Giulia Costa, Emmanuel Onaivi, Nicola Simola
BACKGROUND: Rats emit 50-kHz ultrasonic vocalizations (USVs) in response to non-pharmacological and pharmacological stimuli, with addictive psychostimulants being the most effective drugs that elicit calling behavior in rats. Earlier investigations found that dopamine D1-like and D2-like receptors modulate the emission of 50-kHz USVs stimulated in rats by the acute administration of addictive psychostimulants. Conversely, information is lacking on how dopamine D1-like and D2-like receptors modulate calling behavior in rats that are repeatedly treated with addictive psychostimulants...
January 4, 2024: International Journal of Neuropsychopharmacology
(no author information available yet)
No abstract text is available yet for this article.
December 27, 2023: International Journal of Neuropsychopharmacology
Nurhumar Kurban, Yu Qin, Hui-Ling Zhao, Xiao Hu, Xi Chen, Yi-Yi Zhao, Yu-Shuo Peng, Hong-Bo Wang, Su-Ying Cui, Yong-He Zhang
BACKGROUND: Melanin-concentrating hormone (MCH) is a hypothalamic neuropeptide that projects throughout the central nervous system, including the noradrenergic locus coeruleus (LC). Our previous study suggested that MCH/MCH receptor 1 (MCHR1) in the LC may be involved in the regulation of depression. The present study investigated whether the role of MCH/MCHR1 in the LC in depression-like behaviors is associated with the regulation of norepinephrine. METHOD: Chronic unpredictable stress (CUS) and an acute intra-LC microinjection of MCH induced depression-like behaviors in rats...
December 22, 2023: International Journal of Neuropsychopharmacology
Joakim Ekstrand, Akihiro Takamiya, Axel Nordenskjold, George Kirov, Pascal Sienaert, Charles Kellner, Pouya Movahed Rad
Two recent clinical trials, KetECT and ELEKT-D, compared the effectiveness of ketamine and electroconvulsive therapy (ECT) for major depressive disorder. Notably, these trials reported marked differences in ECT's clinical outcomes of, with remission rates of 63% for KetECT and a strikingly lower rate of 22% for ELEKT-D, while the remission rates for ketamine were 46% and 38%, respectively. Considering that the primary objective of both trials was to compare the standard treatment (ECT) with an experimental intervention (ketamine), it is crucial to highlight the pronounced disparities in ECT's clinical outcomes...
December 19, 2023: International Journal of Neuropsychopharmacology
Ya-Bin Zheng, Xiao-Ming Sheng, Xiang Jin, Wei Guan
BACKGROUND: Depression is a neuropsychiatric disease with high disability rate and mainly caused by the chronic stresses or genetic factors. There is increasing evidences that miRNAs play a critical role in the pathogenesis of depression. However, the underlying molecular mechanism for the pathophysiology of depression of miRNA remains entirely unclear so far. METHODS: We first established a Chronic Social Defeat Stress (CSDS) mice model of depression, and depression-like behaviors of mice were evaluated by a series of behavioral tests...
December 1, 2023: International Journal of Neuropsychopharmacology
Suyi Shao, Yi Zou, Kody G Kennedy, Mikaela K Dimick, Bradley J MacIntosh, Benjamin I Goldstein
BACKGROUND: Inflammation is implicated in the neuropathology of bipolar disorder (BD). The association of C-reactive protein (CRP) with brain structure has been examined in relation to BD among adults but not youth. METHODS: Participants included 101 youth (BD, n=55; control group [CG], n=46; aged 13-20 years). Blood samples were assayed for levels of CRP. T1-weighted brain images were acquired to obtain cortical surface area (SA), volume, and thickness for three regions of interest (ROI; whole-brain cortical gray matter, prefrontal cortex (PFC), orbitofrontal cortex (OFC)) and for vertex-wise analyses...
November 8, 2023: International Journal of Neuropsychopharmacology
Guangfei Li, Dandan Zhong, Bao Li, Yu Chen, Lin Yang, Chiang-Shan R Li
BACKGROUND: The basal nucleus of Meynert (BNM), a primary source of cholinergic projections to the cortex, plays key roles in regulating sleep-wake cycle and attention. Sleep deficit is associated with impairment in cognitive and emotional functions. However, whether or how cholinergic circuit, sleep, cognitive/emotional dysfunction are inter-related remains unclear. METHODS: We curated the Human Connectome Project data and explored BNM resting state functional connectivities (rsFC) in relation to sleep deficit, based on the Pittsburgh Sleep Quality Index (PSQI), cognitive performance, and subjective reports of emotional states in 687 young adults (342 women)...
October 31, 2023: International Journal of Neuropsychopharmacology
Chieh-Hsin Lin, Hsin-Yi Liao, Hsien-Yuan Lane, Chao-Jung Chen
BACKGROUND: N-methyl-D-aspartate receptors (NMDARs) are crucial components of brain function involved in memory and neurotransmission. Sodium benzoate is a promising NMDAR enhancer and has been proven to be a novel, safe and efficient therapy for patients with Alzheimer's disease (AD). However, in addition to the role of sodium benzoate as an NMDA enhancer, other mechanisms of sodium benzoate in treating AD are still unclear. To elucidate the potential mechanisms of sodium benzoate in Alzheimer's disease, this study employed label-free quantitative proteomics to analyze serum samples from AD cohorts with and without sodium benzoate treatment...
October 24, 2023: International Journal of Neuropsychopharmacology
Rachal D Penrod, Makoto Taniguchi, Angela M Kearns, Jordan L Hopkins, Carmela M Reichel
BACKGROUND: Little is known about the specific roles of cortical and accumbal oxytocin receptors in drug use disorder. To better understand the importance of the endogenous oxytocin system in cocaine relapse behavior, we developed an adeno-associated viral vector (AAV) expressing short hairpin (sh) RNAs to selectively degrade the rat OxyR mRNA in vivo. METHODS: Male (Sprague-Dawley) rats received bilateral infusions of the shRNA for the oxytocin receptor (shOxyR) or an shRNA control virus (shCntrl) into the prefrontal cortex (PFC) or the nucleus accumbens core (NAc)...
October 24, 2023: International Journal of Neuropsychopharmacology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.